

Please type a plus sign (+) inside this box ☒

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

PRD-19NPUS

First Inventor

KUO et al

Title

SUBSTITUTED TRIAZINE KINASE  
INHIBITORS

Express Mail Label No.

EV 139477845 US

**APPLICATION ELEMENTS**

See MPEP Chapter 600 concerning utility patent application contents.

**ADDRESS TO:** Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(submit an original and a duplicate for fee processing)

2. ☐ Applicant claims small entity status.

3. ☒ Specification [Total Pages 62]

(Preferred arrangement set forth below)

- Descriptive Title of the Invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R&D
- Reference to sequence listing, a table, or a computer program listing appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

4. ☐ Drawing(s) (35 USC 113) [Total Sheets ]

5. Oath or Declaration [Total Pages 4]

a. ☒ Newly unexecuted (original or copy)

b. Copy from a prior application (37 CFR 1.63(d))

(for continuation/divisional with Box 18 completed)

i. ☐ **DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).

6. ☐ Application Data Sheet. See 37 CFR 1.76

18. ☐ If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-Part (CIP) of prior application No.: , filed

Prior application information: Examiner Group Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**19. CORRESPONDENCE ADDRESS**

☒ Customer Number or Bar Code Label 000027777 or ☐ Correspondence Address below

Name: Philip S. Johnson, Esq.

Address: Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003 USA

**20. TELEPHONE CONTACT**

Please direct all telephone calls or telefaxes to Myra H. McCormack at:

Telephone: (732) 524-6932 Fax: (732) 524-2808

**21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

NAME Myra H. McCormack

Reg. No. 36,602

SIGNATURE

DATE July 18, 2003

19972 U.S. PTO

10/622721



07/18/03

IN THE UNITED STATES  
PATENT AND TRADEMARK OFFICE

Applicant: KUO et. al.

For : SUBSTITUTED TRIAZINE KINASE INHIBITORS

Express Mail Certificate

"Express Mail" mailing number: EV 139477845 US


Date of Deposit: July 18, 2003

I hereby certify that this complete application, including specification pages, claims, assignment, and an unexecuted Combined Declaration and Power of Attorney, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

A Combined Declaration and Power of Attorney will be submitted to the United States Patent and Trademark Office upon receipt of the U.S. Serial Number for this patent application.

Karen Hall-Morgan

(Typed or printed name of person mailing paper or fee)

A handwritten signature in black ink, appearing to read 'Karen Hall-Morgan', written over a horizontal line.

(Signature of person mailing paper or fee)